These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28663209)

  • 1. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.
    Krammer F; García-Sastre A; Palese P
    Cold Spring Harb Perspect Biol; 2018 Jul; 10(7):. PubMed ID: 28663209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal influenza vaccines, science fiction or soon reality?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal influenza virus vaccines and therapeutic antibodies.
    Nachbagauer R; Krammer F
    Clin Microbiol Infect; 2017 Apr; 23(4):222-228. PubMed ID: 28216325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a universal influenza vaccine: different approaches for one goal.
    Sautto GA; Kirchenbaum GA; Ross TM
    Virol J; 2018 Jan; 15(1):17. PubMed ID: 29370862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
    Ross TM
    J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal influenza vaccines: from viruses to nanoparticles.
    Wang Y; Deng L; Kang SM; Wang BZ
    Expert Rev Vaccines; 2018 Nov; 17(11):967-976. PubMed ID: 30365905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the development of influenza virus vaccines.
    Krammer F; Palese P
    Nat Rev Drug Discov; 2015 Mar; 14(3):167-82. PubMed ID: 25722244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.
    Zhang Y; Xu C; Zhang H; Liu GD; Xue C; Cao Y
    Viruses; 2019 Apr; 11(5):. PubMed ID: 31052339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliciting broadly protective antibody responses against influenza.
    Kirchenbaum GA; Ross TM
    Curr Opin Immunol; 2014 Jun; 28():71-6. PubMed ID: 24632083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal influenza vaccines: a realistic option?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S120-S124. PubMed ID: 27130671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Antigens for Universal Influenza Vaccine Development.
    Nguyen QT; Choi YK
    Viruses; 2021 May; 13(6):. PubMed ID: 34073996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.
    Krammer F
    Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to influenza virus infection.
    Kreijtz JH; Fouchier RA; Rimmelzwaan GF
    Virus Res; 2011 Dec; 162(1-2):19-30. PubMed ID: 21963677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Platforms for the Development of a Universal Influenza Vaccine.
    Kumar A; Meldgaard TS; Bertholet S
    Front Immunol; 2018; 9():600. PubMed ID: 29628926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
    Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.